Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease |
| |
| Institution: | 1. Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, United States;2. Naval Medical Center of San Diego, San Diego, CA, United States;3. The Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States;4. Madigan Army Medical Center, Tacoma, WA, United States;5. San Antonio Military Medical Center, San Antonio, TX, United States;6. Naval Health Research Center, San Diego, CA, United States;7. Walter Reed National Military Medical Center, Bethesda, MD, United States;1. Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada;3. Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada;4. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada;5. Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada;7. Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada;6. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;12. Department of Surgery, University of Toronto, Toronto, Ontario, Canada;8. Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada;1. Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea;2. Department of Neurosurgery, Seoul National University Bundang Hospital, 173-82 Gumi-Ro, Bundang-Gu, Seongnam, Gyeonggi-Do, Republic of Korea;3. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea;1. Department of Surgery, Yamamoto-Hidehiro Clinic, Tokyo, Japan;2. Department of Surgery, Kobe Health University, Kobe, Japan |
| |
| Abstract: | BackgroundThe moderate level of protection conferred by influenza vaccines is well-known, but the vaccine's ability to attenuate symptom severity among vaccinated individuals (i.e., vaccine failures) has not been established.MethodsWe enrolled otherwise healthy adults who presented with influenza-like illness (ILI) at five US military hospitals between 2009 and 2014. Influenza was diagnosed and subtyped by PCR. Individual and composite severity scores were compared between those who had vs. had not received the seasonal influenza vaccine >14 days prior to enrollment.ResultsA total of 155 cases of influenza (A/H1N1, n = 69; A/H3N2, n = 66; A/untyped, n = 3; B, n = 17) were identified, of whom 111 (72%; A/H1N1, n = 44; A/H3N2, n = 52; A/untyped, n = 3; B, n = 12) had been vaccinated. Women were significantly less likely to be vaccinated than men (49% vs. 89%; p < 0.01). In multivariate analysis, vaccinated individuals were significantly less likely to report a fever >101 °F (OR 0.24; 95% CI 0.10, 0.62]) and more likely to report myalgias (OR 3.31; 95% CI 1.22, 8.97]) than vaccinated individuals. Among patients with A/H3N2 infection, upper respiratory and total symptom severity scores were significantly lower for vaccinated patients during the first 2 days of illness, and differences in total symptom severity persisted over 7 days (p < 0.05 for all comparisons). Differences across additional symptom categories (lower respiratory and systemic) were also observed throughout 7 days of illness in bivariate analyses. Differences in symptom severity were not observed between vaccinated and unvaccinated participants with A/H1N1 infection.ConclusionsAmong patients with A/H3N2 infection, receipt of seasonal influenza vaccine was associated with reduced symptom severity. Patient-centered discussion about the benefits of influenza vaccination should be expanded to include the possibility that the vaccine could attenuate symptoms. |
| |
| Keywords: | Influenza Vaccine Severity Military |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
